scholarly journals P8‐153: Real‐data analysis of the combination of an immune checkpoint inhibitor to platinum doublet chemotherapy for small cell lung cancer patients

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 348-348
Keyword(s):  
Lung Cancer ◽  
Data Analysis ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Real Data ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Doublet Chemotherapy ◽  
Platinum Doublet

Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study

Lung Cancer ◽  
2015 ◽  
Vol 90 (3) ◽  
pp. 427-432 ◽  
Author(s):  
Denis Moro-Sibilot ◽  
Egbert Smit ◽  
Javier de Castro Carpeño ◽  
Krzysztof Lesniewski-Kmak ◽  
Joachim G. Aerts ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
Doublet Chemotherapy ◽  
Platinum Doublet

scholarly journals Effectiveness of corticosteroids on immune checkpoint inhibitor-induced interstitial pneumonia among patients with a history of interstitial pneumonia: A case series

2021 ◽  
Vol 9 ◽  
pp. 2050313X2110313
Author(s):  
Takenori Ichimura ◽  
Miwa Hinata ◽  
Daisuke Ichikura ◽  
Shinya Suzuki
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Interstitial Pneumonia ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
History Of

There are few reports on the effectiveness of corticosteroids for immune checkpoint inhibitor-induced interstitial pneumonia in patients with a history of interstitial pneumonia. We report on 10 non-small cell lung cancer patients with a history of interstitial pneumonia who experienced immune checkpoint inhibitor-induced interstitial pneumonia. The immune checkpoint inhibitor-induced interstitial pneumonia lasted for a median duration of 41.5 days (range = 22–127 days). Eight of the ten patients responded to corticosteroid monotherapy; one patient responded to corticosteroids and the immunosuppressant, tacrolimus; and one patient did not improve after corticosteroid treatment. In non-small cell lung cancer patients with a history of interstitial pneumonia, immune checkpoint inhibitor-induced interstitial pneumonia was generally responds to corticosteroids.

Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21034-e21034
Author(s):  
Hiromi Watanabe ◽  
Toshio Kubo ◽  
Kiichiro Ninomiya ◽  
Daisuke Minami ◽  
Kenichiro Kudo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document